Celcuity (CELC) closed at $64.32 on November 11, 2026, down 4.1% from the previous close, on volume of 658,461 shares (30-day average 1,624,964).
Data as of November 11, 2026.
| # | Date | Strategy | Legs | Contracts |
|---|---|---|---|---|
| 1 | Nov 6, 2026 | Calendar Put Spread | 18-Dec-26 : 15-Jan-27 65 P | 2,980 |
| 2-3 | The next 2 largest trades are for Premium members. Start a 7-day free trial | |||
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 11, 2026. See the 10 largest for 30, 60 and 90 days
Globe Newswire (Mon, 9-Nov 8:30 AM ET)
Celcuity Inc. Reports Third Quarter 2026 Financial Results and Provides Corporate Update
Globe Newswire (Thu, 5-Nov 4:01 PM ET)
Celcuity To Participate in Upcoming Investor Conferences
Globe Newswire (Tue, 3-Nov 8:30 AM ET)
Celcuity Schedules Release of Third Quarter 2026 Financial Results and Webcast/Conference Call
Globe Newswire (Thu, 29-Oct 8:30 AM ET)
Globe Newswire (Sat, 24-Oct 4:15 AM ET)
Globe Newswire (Fri, 23-Oct 9:15 AM ET)
Globe Newswire (Mon, 5-Oct 8:00 AM ET)
Celcuity Appoints David Gryska To Its Board Of Directors
Globe Newswire (Fri, 2-Oct 8:00 AM ET)
Market Chameleon (Wed, 30-Sep 5:19 AM ET)
Celcuity Announces That REVTORPYK (gedatolisib) Is Now Commercially Available In The United States
Globe Newswire (Wed, 30-Sep 8:00 AM ET)
Celcuity Inc is a clinical-stage biotechnology company developing targeted therapies for multiple solid tumors. Its candidate, gedatolisib, is a kinase inhibitor of the PI3K/AKT/mTOR (PAM) pathway, binding all class I PI3K isoforms and mTORC1/2, offering comprehensive inhibition with a mechanism and pharmacokinetics differentiated from other therapies. The Phase 3 VIKTORIA-1 trial, evaluating gedatolisib with fulvestrant, with or without palbociclib, in HR+/HER2- breast cancer, has completed enrollment and reported results for PIK3CA WT tumors, with cohort 2 (PIK3CA MT) also enrolled. Phase 3 VIKTORIA-2 and Phase 1b/2 CELC-G-201 trials, evaluating combinations in endocrine-resistant HR+/HER2- breast cancer and metastatic castration-resistant prostate cancer, are ongoing.
Celcuity trades on the NASDAQ stock market under the symbol CELC.
As of November 12, 2026, CELC stock price climbed to $65.42 with 318,738 million shares trading.
CELC has a beta of 1.93, meaning it tends to be more sensitive to market movements. CELC has a correlation of 0.13 to the broad based SPY ETF.
CELC has a market cap of $3.20 billion. This is considered a Mid Cap stock.
Last quarter Celcuity reported $0 in Revenue and -$1.21 earnings per share. This fell short of revenue expectation by $-881,280 and exceeded earnings estimates by $.31.
In the last 3 years, CELC traded as high as $151.02 and as low as $7.58.
The top ETF exchange traded funds that CELC belongs to (by Net Assets): VTI, XBI, IWM, VXF, IWO.
CELC has underperformed the market in the last year with a price return of -17.4% while the SPY ETF gained +12.5%. CELC has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -25.8% and -5.8%, respectively, while the SPY returned -1.0% and -1.5%, respectively.
CELC support price is $61.74 and resistance is $66.91 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CELC shares will trade within this expected range on the day.
